Compounds that affect the formation of sPLA2 include IL-6 inhibitors such as tocilizumab, as well as potential IL-6 blockers including sarilumab, ALX-0061, sirukumab, MEDI5117, clazakizumab, and olokizumab.61 Infliximab, a chimeric monoclonal TNF-alpha antibody, is used to treat a number of autoimmune diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. Here, IL6 is linked to Behcet disease.